Navigation Links
Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets
Date:5/12/2010

AZIL, THROUGH 2014 79

TABLE 60 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN BRAZIL, THROUGH 2014 80

CHINA 80

MARKET OVERVIEW 80

REGULATORY CONSIDERATIONS 80

PATENT CONSIDERATIONS 81

TABLE 61 FORECAST EPIDEMIOLOGY: WET AMD IN CHINA, THROUGH 2014 82

TABLE 62 FORECAST EPIDEMIOLOGY: DRY AMD IN CHINA, THROUGH 2014 82

TABLE 63 FORECAST EPIDEMIOLOGY: GLAUCOMA IN CHINA, THROUGH 2014 82

TABLE 64 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CHINA, THROUGH 2014 83

TABLE 65 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CHINA, THROUGH 2014 83

INDIA 83

MARKET OVERVIEW 83

REGULATORY CONSIDERATIONS 84

PATENT CONSIDERATIONS 84

TABLE 66 FORECAST EPIDEMIOLOGY: WET AMD IN INDIA, THROUGH 2014 85

TABLE 67 FORECAST EPIDEMIOLOGY: DRY AMD IN INDIA, THROUGH 2014 85

TABLE 68 FORECAST EPIDEMIOLOGY: GLAUCOMA IN INDIA, THROUGH 2014 85

TABLE 69 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN INDIA, THROUGH 2014 86

TABLE 70 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN INDIA, THROUGH 2014 86

RUSSIA 86

MARKET OVERVIEW 86

REGULATORY CONSIDERATIONS 8
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ANDOVER, Mass. , Oct. 1, 2014 /PRNewswire/ ... ; AEX: PHIA) today announced its eCareCoordinator and ... the U.S. Food and Drug Administration (FDA). A ... of telehealth programs , eCareCoordinator and eCareCompanion are ... are the first clinical applications to be available ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... Calif., Sept. 19, 2011 Amgen (NASDAQ: ... Drug Administration (FDA) approved two new indications for Prolia® ... women at high risk for fracture receiving adjuvant aromatase ... to increase bone mass in men at high risk ...
... Sept. 19, 2011 Boston Scientific Corporation (NYSE: ... a highly deliverable and ultra-low profile 0.014 inch balloon ... procedures below the knee.  The Company has begun marketing ... markets.   Boston Scientific developed the Coyote ...
Cached Medicine Technology:FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 2FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 3FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 4FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 5FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 6FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 7FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 8Boston Scientific Launches Coyote™ Balloon Catheter 2Boston Scientific Launches Coyote™ Balloon Catheter 3Boston Scientific Launches Coyote™ Balloon Catheter 4
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... four months of hormonal therapy before and with ... by as much as eight yearsespecially the development ... with potentially aggressive prostate cancer. This neoadjuvant hormonal ... developing bone metastases avoid long-term hormonal therapy later ...
... immune cells seems to halt the cells typical job ... study by Johns Hopkins researchers suggests. The findings ... ranging from annoying bouts of hay fever to deadly ... his colleagues at the Johns Hopkins Asthma and Allergy ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... 2008) Athanasios Zavras began receiving messages from distraught ... meds to bone death in the jaw. A number ... these drugs to postpone dental work, fearing that procedures ... when Zavras, an associate professor in the Harvard School ...
... (ACP) has received a Commonwealth Fund grant of nearly $225,000 ... The grant, part of the Commonwealth Funds Patient-Centered Primary ... in November. ACP committed matching funds late in 2007. ... goal is to put the needs of the patient first. ...
... use of opioid drugs to relieve severe pain, black ... to receive these pain-relievers in emergency rooms, according to ... for more than 150,000 pain-related visits to U.S. hospitals ... of whites received opioid drugs compared with only 23 ...
Cached Medicine News:Health News:Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years 2Health News:Protein a possible key to allergy and asthma control 2Health News:Protein a possible key to allergy and asthma control 3Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:American College of Physicians receives grant to study cost of patient-centered medical home 2Health News:Blacks, Hispanics less likely to get strong pain drugs in emergency rooms 2
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Coronary angiographic catheter...
Leksell Neuro Generator is a complete system for stereotactic lesioning, pain treatment, stimulation and bipolar coagulation. It features a radio frequency (RF) energy source with sophisticated, inte...
Medicine Products: